David W. Carley
Technik-/Wissenschafts-/F&E-Leiter bei Pier Pharmaceuticals, Inc.
Profil
David W.
Carley is currently the Director & Chief Scientific Officer at Pier Pharmaceuticals, Inc. and a Professor at the University of Illinois.
He was formerly a Director at RespireRx Pharmaceuticals, Inc. Carley received a doctorate degree from Harvard University in 1985, a doctorate degree from Massachusetts Institute of Technology, and a graduate degree from Massachusetts Institute of Technology in 1982.
Aktive Positionen von David W. Carley
| Unternehmen | Position | Beginn |
|---|---|---|
Pier Pharmaceuticals, Inc.
 Pier Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Pier Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company which develops a pharmacologic treatment for obstructive sleep apnea (OSA). It develops Dronabinol a synthetic derivative of the naturally occurring substance in the cannabis plant, namely delta-9-tetrahydrocannabinol, otherwise known as delta-9 THC. The company was founded in 2007 and is headquartered in Louiseville, CO. | Technik-/Wissenschafts-/F&E-Leiter | 29.06.2011 |
| University of Illinois | Corporate Officer/Principal | 29.06.2011 |
Ehemalige bekannte Positionen von David W. Carley
| Unternehmen | Position | Ende |
|---|---|---|
| RESPIRERX PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | - |
Ausbildung von David W. Carley
| Massachusetts Institute of Technology | Graduate Degree |
| Harvard University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| RESPIRERX PHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Pier Pharmaceuticals, Inc.
Pier Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Pier Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company which develops a pharmacologic treatment for obstructive sleep apnea (OSA). It develops Dronabinol a synthetic derivative of the naturally occurring substance in the cannabis plant, namely delta-9-tetrahydrocannabinol, otherwise known as delta-9 THC. The company was founded in 2007 and is headquartered in Louiseville, CO. | Health Technology |
